Global pharma major Lupin has announced the launch of Glucagon for Injection USP, 1mg/vial, packaged in an emergency kit in the United States.

Glucagon for Injection USP, 1mg/vial, packaged in an emergency kit and is bioequivalent to Glucagon for Injection, 1 mg/vial of Eli Lilly and Company. Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus and as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients, the company said in a statement.

Glucagon for Injection USP, 1mg/vial packaged in an emergency kit, had an estimated annual sale of USD 122 million in the US (IQVIA MAT June 2025).

Lupin specialises in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company enjoys a strong position in India and the US across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. It has 15 state-of-the-art manufacturing sites and 7 research centres globally.